Insight Molecular Diagnostics (IMDX) FCF Margin (2020 - 2026)
Insight Molecular Diagnostics (IMDX) posted FCF Margin of 25787.5% for Q1 2026, down 4081.66% sequentially from 616.68% in Q4 2025, and down 2550004.0% YoY from N/an in Q1 2025.
Insight Molecular Diagnostics (IMDX) FCF Margin (2020 - 2026) Analysis & Trends
Insight Molecular Diagnostics has reported FCF Margin for 7 years, with the latest figure at 25787.5% in Q1 2026.
- Quarterly FCF Margin fell 2550004.0% year-over-year to 25787.5% in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 1409.7% (down 79827.0% YoY) and the FY2025 annual result came in at 625.62%, up 50170.0% from the prior year.
- FCF Margin retreated to 25787.5% in Q1 2026 per IMDX's latest filing, from 616.68% in the prior quarter.
- Over five years, FCF Margin peaked at 261.97% in Q4 2022 and troughed at 25787.5% in Q1 2026.
- A 5-year average of 4423.09% and a median of 1492.99% in 2023 frame the typical range for FCF Margin.
- The sharpest annual moves came in 2023 and 2026: FCF Margin soared 1754396 bps in 2023, then tumbled 2550004 bps in 2026.
- Over 5 years, FCF Margin stood at 261.97% in 2022, then sank by 470 bps to 1492.99% in 2023, then surged by 75 bps to 374.5% in 2024, then slumped by 65 bps to 616.68% in 2025, then slumped by 4082 bps to 25787.5% in 2026.
- According to Business Quant data, FCF Margin over the past three periods registered 25787.5%, 616.68%, and 2135.38% for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | FCF Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Thermo Fisher Scientific | 234.15 Bn | 230.09 Bn | 8.34 Bn | 13.97% |
| 2 | Danaher | 152.10 Bn | 147.75 Bn | 3.61 Bn | 20.19% |
| 3 | Natera | 48.48 Bn | 47.38 Bn | 486.15 Mn | -1.15% |
| 4 | Agilent Technologies | 44.35 Bn | 42.55 Bn | 990.00 Mn | 10.95% |
| 5 | Iqvia Holdings | 43.68 Bn | 41.60 Bn | 1.44 Bn | 8.24% |
| 6 | Idexx Laboratories | 43.02 Bn | 42.83 Bn | 779.09 Mn | 26.51% |
| 7 | Illumina | 34.39 Bn | 33.22 Bn | 770.00 Mn | 13.89% |
| 8 | Mettler Toledo International | 28.29 Bn | 28.24 Bn | 650.22 Mn | 27.51% |
| 9 | Labcorp Holdings | 27.51 Bn | 27.37 Bn | 1.11 Bn | 8.41% |
| 10 | Insight Molecular Diagnostics | 158.03 Mn | 139.50 Mn | 157,000.00 | -4,203.77% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -4,203.77% |
| Mar 31, 2026 | -25,787.50% |
| Dec 31, 2025 | -616.68% |
| Sep 30, 2025 | -2,183.08% |
| Jun 30, 2025 | -1,259.27% |
| Mar 31, 2025 | -287.46% |
| Dec 31, 2024 | -374.50% |
| Sep 30, 2024 | -4,884.35% |
| Jun 30, 2024 | -5,931.73% |
| Mar 31, 2024 | -2,189.77% |
| Dec 31, 2023 | -1,492.99% |
| Sep 30, 2023 | -747.09% |
| Jun 30, 2023 | -1,475.59% |
| Mar 31, 2023 | -2,794.61% |
| Dec 31, 2022 | -1,230.86% |
| Sep 30, 2022 | -1,290.00% |
| Jun 30, 2022 | -675.68% |
| Mar 31, 2022 | -1,421.26% |
| Dec 31, 2021 | -208.02% |
| Sep 30, 2021 | -1,156.20% |